A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

PHASE1RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2027

Conditions

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis

Interventions

DRUG

ALN-CIDEB

Administered per the protocol

DRUG

Placebo

Administered per the protocol

Trial Locations (2)

RECRUITING

Richmond Pharmacology Limited, London

RECRUITING

Parexel International Early Phase Clinical Unit, Harrow

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY